Evaluation of the efficacy of totally implantable venous access port in breast cancer patients undergoing chemotherapy.

Abstract

Objective: The use of Totally Implantable Venous Access Port (TIVAP) has gained importance in chemotherapy for cancer patients due to its ability to reduce complications compared to conventional central venous catheters. Chemotherapy for breast cancer often requires long-term venous access, and the choice of device can impact both treatment efficacy and patient quality of life. This study randomly divided 355 breast cancer chemotherapy patients, who were treated from January 2022 to January 2023, into the TIVAP group (n = 177) and the control group (n = 178) to evaluate the application effect of TIVAP.

Methods: The patients in the TIVAP group used totally implantable venous access ports, while those in the control group used central venous catheters. We compared the clinical efficacy, ability of daily life, complications, and patient satisfaction between the two groups. Statistical analysis was performed using t-tests for continuous data and χ2 tests for categorical data.

Results: Our results showed that the total clinical efficacy was 96.61% in the TIVAP group and 90.45% in the control group, and the data of the two groups were significantly different (P < 0.05). Before the intervention, the daily living ability scores of the two groups were analyzed, and the difference between the two groups was not significant (P > 0.05). After the intervention, the daily living ability scores of the patients in the TIVAP group (77.41 ± 7.02) were significantly higher than those of the control group (66.75 ± 6.42) (P < 0.05).In terms of complication rate, the TIVAP group was 5.08%, which was significantly lower than that of the control group (12.36%), and the difference between the two groups was significant (P < 0.05).

Conclusion: Therefore, the application of TIVAP in breast cancer chemotherapy patients can effectively reduce the toxic and side effects of chemotherapy, ensure that the patients use the drugs according to the chemotherapy cycle, and then improve the clinical outcome.